Immunovia’s vision is to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.
IMMray™ PanCan-d is the first blood-based test dedicated to early detection of pancreatic cancer. It is exclusively available as a laboratory developed test (LDT) from Immunovia, Inc., Marlborough, USA.
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see www.immunoviainc.com.
Immunovia has initiated since 2016 a prospective clinical validation program for high risk groups for pancreatic cancer involving 30 hospitals and over 10,000 patients from USA and Europe.
Immunovia Interim Report January-March 2023 presentation from 23 May, 2023, with Jeff Borcherding, CEO & President and Karin Almqvist Liwendahl, Chief Financial Officer.
Immunovia AB published the company’s Interim Report January-March 2023 on Tuesday, May 23, 2023, at 8:30 am CET.